Consistent with these data, NMN levels within tumor masses were found to be significantly reduced in the combination treatment arm, as compared to those measured in mice that had been treated with FK866 alone (Figure 4B), which is in keeping with the involvement of NMN as an intermediate metabolite of both NAMPT- and NRK-mediated pathways of NAD+ production (Figure 1A). This evidence concerns the gene NTS and neoplasm.